Healthcare Professionals

The goal of Biothera Pharmaceuticals’ current Phase 2 clinical trials is to demonstrate the safety and efficacy of combining Imprime PGG and pembrolizumab (KEYTRUDA®) in multiple cancer indications.

IMPRIME-1 is a clinical trial evaluating the effectiveness of this therapeutic combination in patients with advanced melanoma or triple negative breast cancer whose disease has progressed following prior treatment with checkpoint inhibitor therapy or chemotherapy.

Imprime PGG has been safely administered to more than 400 human subjects. There have been no overlapping toxicities with common chemotherapy regimens or other monoclonal antibodies. The most common adverse events are mild-to-moderate infusion reactions.  Any side effects additive to background therapy have been manageable.

Imprime PGG Drives an Integrated Anti-Cancer Immune Response to Potentiate Immune Checkpoint Inhibitor Therapies
Jeremy Graff, Ph.D., Chief Scientific Officer, Biothera Pharmaceuticals

Melanoma/Triple Negative Breast Cancer Phase 2 Study Protocol
Richard Huhn, M.D., Senior Vice President and Medical Director, Biothera Pharmaceuticals

Imprime PGG: Anti-Glucan Antibody (ABA) Levels Represent a Mechanism-Based Patient Selection Biomarker
Jeremy Graff, Ph.D., Chief Scientific Officer, Biothera Pharmaceuticals